Episode Details

Rapid Micro Biosystems starts 2026 with robust Q1 results, reporting a 11% revenue increase to $8M, driven by a 36% surge in product revenue and a 28% rise in recurring revenue. The company places six Growth Direct systems, totaling 196 worldwide, and expands partnerships with MilliporeSigma into new markets. Strong customer responses, including multisystem orders from Samsung Biologics, reflect broader industry shifts toward QC standardization. Rapid Micro reaffirms full-year revenue guidance and expects thirty to thirty-eight system placements, with gross margins hitting mid to high teens. The company is well-positioned with $23M in cash and $25M available on credit line for continued automation growth.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/528b1770409acd81